XML 19 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Oct. 31, 2018
Oct. 31, 2017
Cash flows from operating activities    
Net loss $ (91,730) $ (69,985)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 3,334 2,789
Stock-based compensation 26,850 15,066
Amortization of debt discount and issuance costs 4,233 0
Non-cash interest on office financing lease 659 0
Deferred income taxes (351) 163
Change in fair value of warrant liability 0 (101)
Change in operating assets and liabilities:    
Accounts receivable 9,267 (4,653)
Prepaid expenses and other current assets (4,018) (2,120)
Deferred commissions (5,514) (2,217)
Other long-term assets (33) (670)
Accounts payable (165) 687
Deferred rent 1,258 (85)
Accrued liabilities 7,184 2,163
Deferred revenue 16,517 21,794
Net cash used in operating activities (32,509) (37,169)
Cash flows from investing activities    
Purchases of property and equipment (3,698) (1,714)
Proceeds from maturities of marketable securities 206,000 74,230
Purchases of marketable securities (369,736) (72,879)
Net cash used in investing activities (167,434) (363)
Cash flows from financing activities    
Proceeds from exercise of stock options, including early exercised stock options 17,631 8,201
Proceeds from the issuance of common stock under the Employee Stock Purchase Plan 5,626 0
Repurchase of early exercised stock options (327) (149)
Proceeds from borrowings on convertible senior notes, net of issuance costs 291,145 0
Payment for purchase of capped calls (37,086) 0
Proceeds from tenant improvement allowance on build-to-suit lease 633 0
Proceeds from the IPO, net of underwriting discounts and commissions 0 205,494
Proceeds from exercise of redeemable convertible preferred stock warrants 0 1
Payment of initial public offering costs 0 (2,344)
Net cash provided by financing activities 277,622 211,203
Effect of exchange rate changes on cash, cash equivalents, and restricted cash (101) 182
Net increase in cash, cash equivalents and restricted cash 77,578 173,853
Cash, cash equivalents and restricted cash, beginning of period 62,427 69,412
Cash, cash equivalents and restricted cash, end of period 140,005 243,265
Supplemental cash flow disclosure of noncash investing and financing activities    
Vesting of early exercised stock options 1,045 950
Costs related to initial public offering included in accounts payable and accrued liabilities 0 1,529
Conversion of redeemable convertible preferred stock warrant liability to redeemable convertible preferred stock as a result of warrant exercise 0 1,171
Purchases of property and equipment included in accounts payable and accrued liabilities 1,806 0
Construction in progress related to build-to-suit lease obligations $ 11,683 $ 0